Study guide

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants

Key Takeaways Explain This Topic AI

Long-acting reversible contraceptives (LARCs), including intrauterine devices and the subdermal implant, provide Tier 1 contraceptive efficacy with typical-use failure rates under 1% (<0.1% for implant, 0.1–0.2% for LNG-IUS, 0.8% for Cu-IUD), completely removing adherence requirements.

The Copper T 380A IUD (Paragard) is non-hormonal, FDA-approved for up to 10–12 years, acts via a sterile spermicidal foreign-body inflammatory reaction, serves as the gold-standard emergency contraceptive within 5 days of coitus, and characteristically increases menstrual volume and dysmenorrhea.

Levonorgestrel intrauterine systems (52 mg Mirena/Liletta [8 years], 19.5 mg Kyleena [5 years], 13.5 mg Skyla [3 years]) act locally via cervical mucus thickening and profound endometrial decidualization/atrophy, inducing amenorrhea in 20% to 50% of 52 mg users at 1 year, making 52 mg LNG-IUS first-line therapy for heavy menstrual bleeding.

The single-rod etonogestrel implant (Nexplanon, 68 mg; FDA-approved for up to 5 years since January 2026 and dispensed through a REMS program) achieves Tier 1 efficacy primarily via pituitary LH suppression (ovulation inhibition) and cervical mucus thickening; prospective counseling regarding unpredictable, non-cyclical bleeding is the single most effective intervention to prevent premature discontinuation.

LARC complications are managed conservatively: acute mild-to-moderate pelvic inflammatory disease is treated with broad-spectrum antimicrobials with the IUD in situ unless no clinical improvement is observed after 48–72 hours; missing strings require sequential evaluation with a cytobrush, transvaginal ultrasound, and abdominal radiography if perforation is suspected.

Last updated: October 2026

Tier 1 Efficacy & Clinical Rationale for LARC

Contraceptive methods are stratified into three clinical tiers based on typical-use failure rates:

Tier 1 (<1% failure rate): Long-acting reversible contraceptives (LARCs)—including intrauterine devices (IUDs) and subdermal implants—alongside permanent sterilization. These "set-and-forget" methods eliminate user compliance and adherence errors.

Tier 2 (4–9% failure rate): Injectables, oral contraceptive pills, transdermal patches, and vaginal rings.

Tier 3 (10–25%+ failure rate): Barrier methods, fertility awareness-based methods (FABMs), withdrawal, and spermicides.

LARC methods combine Tier 1 efficacy with immediate return of baseline fecundity upon removal. One-year continuation rates for LARCs exceed 80–88%, compared to roughly 50–60% for short-acting methods. ACOG and the CDC endorse LARCs as first-line options for all reproductive-age individuals, including nulliparous women and adolescents.

Copper Intrauterine Device (Paragard)

The Copper T 380A (Paragard) features a radiopaque polyethylene T-frame wrapped with 380 mm² of exposed copper wire on the stem and arms.

Mechanism of Action: Continuous release of copper ions into the uterine cavity and fallopian tubes produces direct spermicidal cytotoxicity, inhibiting sperm motility, capacitation, and acrosome reaction. The foreign body also induces a sterile endometrial inflammatory reaction, preventing fertilization. It does not disrupt established post-implantation pregnancy.

Duration of Use: FDA-approved for up to 10 years; clinical trials demonstrate efficacy for up to 12 years .

Emergency Contraception (EC): Serves as the gold standard for postcoital EC when placed within 5 days (120 hours) of unprotected intercourse (>99.9% efficacy).

Bleeding Profile & Management: As an entirely non-hormonal method, endogenous ovulatory cycles persist. The primary side effect is increased menstrual bleeding (30–50% increase) and dysmenorrhea, predominantly during the first 3 to 6 months. First-line management consists of scheduled NSAIDs (e.g., ibuprofen 600–800 mg TID or mefenamic acid 500 mg TID with meals) taken 1 to 2 days prior to or at menses onset for the first 5 days.

Levonorgestrel Intrauterine Systems (LNG-IUS)

Four levonorgestrel-releasing intrauterine systems are available in the United States:

Device Name Total LNG Mass Initial Daily Release Approved Duration Dimensions & Inserter Outer Diameter Expected 1-Year Amenorrhea Clinical Distinctions

Mirena 52 mg ~20 mcg/day Up to 8 years 32 x 32 mm; Inserter: 4.4 mm 20% (up to 50% by 5 yr) FDA-indicated for contraception and heavy menstrual bleeding (HMB).

Liletta 52 mg ~20 mcg/day Up to 8 years 32 x 32 mm; Inserter: 4.8 mm 19% to 24% FDA-indicated for contraception and HMB; public health pricing.

Kyleena 19.5 mg ~17.5 mcg/day Up to 5 years 28 x 30 mm; Inserter: 3.8 mm 12% Smaller frame and inserter; silver ring for ultrasound visibility.

Skyla 13.5 mg ~14 mcg/day Up to 3 years 28 x 30 mm; Inserter: 3.8 mm 6% Smallest frame; lowest systemic absorption; lower amenorrhea rate.

Mechanism of Action & Bleeding Profiles

LNG-IUS devices act primarily via profound local progestogenic effects: thickening cervical mucus into an impenetrable barrier within 24–48 hours, inducing stromal decidualization and glandular atrophy, and altering uterotubal transport. Ovulation is maintained in the majority of cycles, preserving endogenous estradiol levels.

Unscheduled spotting is common during the first 3 to 6 months. With ongoing endometrial atrophy, flow decreases substantially; by 12 months, 20% to 50% of 52 mg LNG-IUS users develop amenorrhea or oligomenorrhea. Patients should be reassured that amenorrhea results from local endometrial suppression rather than premature menopause or retained blood.

Etonogestrel Subdermal Implant (Nexplanon)

Nexplanon is a single radiopaque ethylene vinyl acetate rod (4 cm x 2 mm) containing 68 mg of etonogestrel , preloaded in a disposable applicator.

Mechanism & Efficacy: Releases 60–70 mcg/day initially, decreasing to 25–30 mcg/day at 3 years. Its primary mechanism is complete ovulation suppression via pituitary LH surge inhibition, supported by rapid cervical mucus thickening. With a failure rate <0.1%, it is the most effective reversible contraceptive available. In January 2026 the FDA extended approval from 3 to 5 years and placed the implant under a REMS program that requires trained, certified inserters.

Bleeding Pattern Counseling: Unpredictable, non-cyclical bleeding is the most common side effect and leading reason for discontinuation (~30% infrequent bleeding, ~20% amenorrhea, ~15–20% frequent/prolonged spotting). The 90-day bleeding pattern predicts long-term bleeding. Bothersome bleeding is managed with a 5- to 7-day course of scheduled NSAIDs (ibuprofen 800 mg TID) or a 10- to 20-day course of low-dose combined oral contraceptives (30–35 mcg EE); US SPR 2024 also lists a 5-day course of tranexamic acid or a 7–10-day course of tamoxifen.

Insertion & Non-Palpable Rods: Placed subdermally in the non-dominant upper inner arm, 8–10 cm proximal to the medial humeral epicondyle, avoiding the biceps-triceps sulcus. Palpation is verified immediately. Non-palpable rods mandate immediate backup contraception; blind exploration is contraindicated. Localize via high-frequency ultrasound (≥10 MHz), non-contrast MRI, or serum etonogestrel assay, followed by specialized surgical extraction.

Clinical Insertion Protocols & Complication Management

Insertion Timing: LARCs can be initiated anytime during the cycle if pregnancy is reasonably excluded (quick start). Backup contraception for 7 days is needed if an implant is placed >5 days, or an LNG-IUD >7 days, after menstrual bleeding started (none for the copper IUD; US SPR 2024). Immediate post-abortion placement is safe and effective. Immediate postplacental placement (within 10 minutes of placental delivery; US MEC 2024 Category 2 for both IUD types) has higher expulsion rates (10–25%) than delayed placement at 4–6 weeks (2–5%), but delivers significantly higher 1-year continuation.

Lost Strings & Perforation: If strings are absent at the os, probe the canal with a cytobrush. If unretrieved, obtain a urine pregnancy test and transvaginal ultrasound. If the uterine cavity is empty, obtain abdominal/pelvic radiographs to evaluate for peritoneal perforation. Uterine perforation occurs in ~1 per 1,000 insertions; major risk factors include active lactation (~6-fold increase due to uterine softening) and insertion ≤36 weeks postpartum.

Important

If acute pelvic inflammatory disease (PID) develops with an IUD in situ, initiate CDC-recommended broad-spectrum antibiotics with the IUD in place . Immediate removal does not accelerate recovery. Remove the device only if clinical improvement is absent after 48 to 72 hours of antimicrobial therapy.